Literature DB >> 20378688

Elevated blood markers 1 year before manifestation of malignant glioma.

Wolfgang Gartner1, Aysegül Ilhan, Dashurie Neziri, Wolfgang Base, Michael Weissel, Adelheid Wöhrer, Harald Heinzl, Thomas Waldhör, Ludwig Wagner, Matthias Preusser.   

Abstract

We detected distinct plasma concentration profiles of S100B, neuropeptide Y, and secretagogin in 3 of 191 patients enrolled in a previous study investigating brain-tissue-related markers in the blood of patients with atrial fibrillation. Intriguingly, 2 of these 3 patients, both of whom were without neurological symptoms at the time of blood sampling, were diagnosed with malignant glioma (MG) approximately 1 year later. To our knowledge, this is the first report indicating that distinct blood biomarker profiles may be detected long before clinical manifestation of MG.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20378688      PMCID: PMC2940699          DOI: 10.1093/neuonc/noq034

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  19 in total

1.  [Serum S100 protein and radiation-induced brain injury in astrocytoma patients].

Authors:  Wei-shu Song; Li-bing Guo; Zhi-yong Hong; Jun-Jie Li; Jun Wu
Journal:  Di Yi Jun Yi Da Xue Xue Bao       Date:  2005-06

2.  Evolution of glioblastoma.

Authors:  Silvia Hofer; Spyros Kollias; Michael Weller
Journal:  Acta Oncol       Date:  2009       Impact factor: 4.089

3.  Leptin and neuropeptide Y plasma levels in children with cancer.

Authors:  Kudret Cağlar; Tezer Kutluk; Ali Varan; Zehra Koray; Canan Akyüz; Bilgehan Yalçin; Belkis Erbaş; Münevver Büyükpamukçu
Journal:  J Pediatr Endocrinol Metab       Date:  2005-05       Impact factor: 1.634

4.  MRI of high-grade astrocytic tumors: early appearance and evolution.

Authors:  K Okamoto; J Ito; N Takahashi; K Ishikawa; T Furusawa; S Tokiguchi; K Sakai
Journal:  Neuroradiology       Date:  2002-02-19       Impact factor: 2.804

5.  Cerebral expression and serum detectability of secretagogin, a recently cloned EF-hand Ca(2+)-binding protein.

Authors:  W Gartner; W Lang; F Leutmetzer; H Domanovits; W Waldhäusl; L Wagner
Journal:  Cereb Cortex       Date:  2001-12       Impact factor: 5.357

6.  Serum levels of S-100B protein and neuron-specific enolase in glioma patients: a pilot study.

Authors:  Maaike J Vos; Tjeerd J Postma; Frans Martens; Bernard M J Uitdehaag; Marines A Blankenstein; W Peter Vandertop; Ben J Slotman; Jan J Heimans
Journal:  Anticancer Res       Date:  2004 Jul-Aug       Impact factor: 2.480

7.  Neuropeptides in neurological tumours.

Authors:  J M Allen; N R Hoyle; J C Yeats; M A Ghatei; D G Thomas; S R Bloom
Journal:  J Neurooncol       Date:  1985       Impact factor: 4.130

8.  Plasma IGFBP-2 levels predict clinical outcomes of patients with high-grade gliomas.

Authors:  Yi Lin; Tao Jiang; Kaijia Zhou; Li Xu; Baoshi Chen; Guilin Li; Xiaoguang Qiu; Tianzi Jiang; Wei Zhang; Sonya W Song
Journal:  Neuro Oncol       Date:  2009-01-22       Impact factor: 12.300

9.  S-100beta protein--serum levels in children with brain neoplasms and its potential as a tumor marker.

Authors:  Anil Rajendra; Philip C Spinella; Henry R Drott; Troy E Dominguez; Leslie Sutton; Mark Helfaer
Journal:  J Neurooncol       Date:  2004-05       Impact factor: 4.130

Review 10.  The 2007 WHO classification of tumours of the central nervous system.

Authors:  David N Louis; Hiroko Ohgaki; Otmar D Wiestler; Webster K Cavenee; Peter C Burger; Anne Jouvet; Bernd W Scheithauer; Paul Kleihues
Journal:  Acta Neuropathol       Date:  2007-07-06       Impact factor: 17.088

View more
  8 in total

1.  Serum microRNA-128 as a biomarker for diagnosis of glioma.

Authors:  Jun Sun; Keman Liao; Xuechao Wu; Jin Huang; Shuai Zhang; Xiaojie Lu
Journal:  Int J Clin Exp Med       Date:  2015-01-15

2.  Exploratory investigation of eight circulating plasma markers in brain tumor patients.

Authors:  Aysegul Ilhan-Mutlu; Ludwig Wagner; Georg Widhalm; Adelheid Wöhrer; Sophie Bartsch; Thomas Czech; Harald Heinzl; Fritz Leutmezer; Daniela Prayer; Christine Marosi; Wolfgang Base; Matthias Preusser
Journal:  Neurosurg Rev       Date:  2012-07-05       Impact factor: 3.042

3.  Evaluation of eight plasma proteins as candidate blood-based biomarkers for malignant gliomas.

Authors:  Ryan P Lange; Allen Everett; Pratima Dulloor; Frederick K Korley; Chetan Bettegowda; Cherie Blair; Stuart A Grossman; Matthias Holdhoff
Journal:  Cancer Invest       Date:  2014-07-14       Impact factor: 2.176

Review 4.  The renaissance of Ca2+-binding proteins in the nervous system: secretagogin takes center stage.

Authors:  Alán Alpár; Johannes Attems; Jan Mulder; Tomas Hökfelt; Tibor Harkany
Journal:  Cell Signal       Date:  2011-10-01       Impact factor: 4.315

Review 5.  Eosinophils in glioblastoma biology.

Authors:  Colleen S Curran; Paul J Bertics
Journal:  J Neuroinflammation       Date:  2012-01-17       Impact factor: 8.322

6.  Suppression of miR-221 inhibits glioma cells proliferation and invasion via targeting SEMA3B.

Authors:  Guilan Cai; Shanshan Qiao; Kui Chen
Journal:  Biol Res       Date:  2015-07-22       Impact factor: 5.612

7.  The Reference Level of Serum S-100B Protein for Poor Prognosis in Patients with Intracranial Extracerebral Hematoma.

Authors:  G Anczykowski; J Kaczmarek; R Jankowski; P Guzniczak
Journal:  EJIFCC       Date:  2011-10-05

Review 8.  S100 B: A new concept in neurocritical care.

Authors:  Omidvar Rezaei; Hossein Pakdaman; Kurosh Gharehgozli; Leila Simani; Amir Vahedian-Azimi; Sina Asaadi; Zahra Sahraei; Mohammadreza Hajiesmaeili
Journal:  Iran J Neurol       Date:  2017-04-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.